Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves

Phase 4 Not yet recruiting 250 enrolled RenJi Hospital

RandomizedParallel-groupOpen-labelPrevention

Summary

this study aims to comprehensively evaluate the efficacy and safety profiles of rivaroxaban and warfarin during the initial postoperative period following surgical bioprosthetic valve in patients.

Timeline

Start: 2024-08-01
Primary completion: 2026-02-28
Completion: 2026-12-31

Publications

Wang X, Zhang C, Pan MM, Lin HW, Xue S, Xie B, Gu ZC. Design and rationale of the multicenter randomized clinical trial (REVERSE): Efficacy and safety of rivaroxaban in the early postoperative period for patients with bioprosthetic valve replacement or valve repair. Int J Cardiol. 2025 Apr 15;425:133023. doi: 10.1016/j.ijcard.2025.133023. Epub 2025 Feb 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivaroxaban	Other / unclassified	15 mg	Oral
Subject	Rivaroxaban	Other / unclassified	20 mg	Oral

Indications

No indication recorded.